Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors

AAPS PharmSci

Volumn 4, Issue 4, 2002, Pages

  Drin, Guillaume ^a   Rousselle, Christophe ^a   Scherrmann, Jean Michel ^b   Rees, Anthony R ^a   Temsamani, Jamal ^a  

^a Synt:em   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Blood brain barrier; Intracellular delivery; Multidrug resistance; Peptide vector

Indexed keywords

CELL RECEPTOR; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; ENKEPHALIN DERIVATIVE; PEPTIDE DERIVATIVE; PROTEGRIN; TRANSACTIVATOR PROTEIN; PEPTIDE;

ANIMAL EXPERIMENT; BIOMEDICINE; BLOOD BRAIN BARRIER; BRAIN REGION; CELL MEMBRANE; CELL NUCLEUS; CENTRAL NERVOUS SYSTEM DISEASE; CYTOPLASM; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; HYDROPHILICITY; INHIBITION KINETICS; MEDICAL RESEARCH; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PROTEIN FAMILY; REVIEW; SHUTTLE VECTOR; ANIMAL; BRAIN; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; PEPTIDES;

EID: 85046914841     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps040426     Document Type: Review

References (59)

1. Brightman MW. Morphology of blood-brain interfaces. Exp Eye Res. 1977;25:1-25.
2. Pardridge WM. New approaches to drug delivery through the blood-brain barrier. Trends Biotechnol. 1994;12:239-245.
3. Pardridge WM. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge, UK: Cambridge University Press; 2001.
4. Jolliet-Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol. 1999;13:16-26.
5. Temsami J, Rousselle, C, Rees, AR, Schermann JM. Vector-mediated drug delivery to the brain. Expert Opin Biol Ther. 2001;1:773-782.
6. Lindgren M, Hällbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2002;21:99-103.
7. Langel U. Cell Penetrating Peptides: Process and Applications. New York, NY: CRC Press; 2002.
8. Oehlke J, Scheller A, Wiesner B, et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta. 1998;1414:127-139.
9. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antannapedia homeodomain translocates through biological membrane. J Biol Chem. 1994;269:10444-10450.
10. Pooga M, Hällbrink M, Zorko M, Langel U. Cell penetration by transportan. FASEB J. 1998;12:67-77.
11. Chaloin L, Vidal P, Heitz A, et al. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. Biochemistry. 1997;36:11179-11187.
12. Vidal P, Chaloin L, Heitz A, et al. Interactions of primary amphipathic vector peptides with membranes: conformational consequences and influences on cellular localization. J Membr Biol. 1998;162:259-264.
13. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272:16010-16077.
14. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000;57:679-686.
15. Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther. 2001;296:124-131.
16. Scheller A, Oehlke J, Wiesner B, et al. Structural requirements for cellular uptake of alpha-helical amphipathic peptides. J Pept Sci. 1999;5:185-194.
17. Dathe M, Schümann M, Wieprecht T, et al. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry. 1996;35:12612-12622.
18. Drin G, Dene, Temsamani J, Brasseur R. Translocation of the pAntp peptide and its amphipathic analogue AP-2AL. Biochemistry. 2001;40:1824-1834.
19. Persson D, ThorePE, NordeB. Penetratin-induced aggregation and subsequent dissociation of negatively charged phospholipid vesicles. FEBS Lett. 2001;505:307-312.
20. Hällbrink M, FloreA, Elmquist A, Pooga M,Bartfai T, Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta. 2001;1515:101-109.
21. Magzoub M, Klik K, Eriksson LE, Langel U, Gräslund A. Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochim Biophys acta. 2001;1517:77-89.
22. Kokryakov VN, Harwig SS, Panyutich EA, et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett. 1993;327:231-236.
23. Aumelas A, Mangoni M, Roumestand C, et al. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem. 1996;237:575-583.
24. Mangoni ME, Aumelas A, Charnet P, et al. Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation. FEBS Lett. 1996;383:93-98.
25. Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI, Kagan BL. Membrane channel formation by antimicrobial protegrins. Biochim Biophys Acta. 1999;1420:23-29.
26. Joliot A, Pernelle C, Deagostin-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A. 1991;88:1864-1868.
27. Le Roux I, Joliot A, Bloch-Gallego E, Prochiantz A, Volovitch M. Neurotrophic activity of the antennapedia homeodomain depends on its specific DNA-binding properties. Proc Natl Acad Sci U S A. 1993;90:9120-9124.
28. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third-helix of the antennapedia homeodomain is receptor-independent. J Biol Chem. 1996;271:18188-18193.
29. Brudigou J, Legrand C, Me J, Rabie. The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurones: a new basis for an efficient intracellular delivery system. Biochem Biophys Res Commun. 1995;214:685-693.
30. Fenton M, Bone N, Sinclair A. The efficient and rapid import of a peptide into primary b and T lymphocytes and a lymphoblastoid cell line. J Immunol Methods. 1998;212:41-48.
31. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55:1189-1193.
32. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91:664-668.
33. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2001;277:2437-2443.
34. Michell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Peptide Res. 2000;56:318-325.
35. Derossi D, Williams EJ, Green PJ, Dunican DJ, Doherty P. Stimulation of mitogenesis by a cell-permeable Pl 3-kinase binding peptide. Biochem Biophys Res Commun. 1998;251:148-152.
36. Hall H, Williams EJ, Moore SE, Walsh FS, Prochiantz A, Doherty P. Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Curr Biol. 1996;6:580-587.
37. Williams EJ, Dunican DJ, Green PJ, et al. Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide. J Biol Chem. 1997;272:22349-22354.
38. Bardelli A, Longati P, Williams TA, Benvenuti S, Comoglio PM. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem. 1999;274:29274-29281.
39. Cussac D, Vidal M, Leprince C, et al. A Soc-derived peptidimer blocks the RAS signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J. 1999;13:31-38.
40. Mutoh M, Lung FD, Long YQ, Roller PP, Sikorski RS, O'Connor PM. A p21 (Warf/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 1999;59:3480-3488.
41. Bonfanti M, Taverna S, Salmona M, D'Incalci M, Broggini M. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 1997;57:1442-1446.
42. Fâhraeus R, Paramio JM, Ball KL, Lain S, Lain DP. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol. 1996;6:84-91.
43. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol. 2001;21:4773-4784.
44. Caron NJ, Torrente Y, Camirand G, et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther. 2001;3:310-318.
45. Embury J, Klein D, Pileggi A, et al. Proteins linked to a protein transduction domain efficiently transduce pancreatic islets. Diabetes. 2001;50:1706-1713.
46. Troy CM, Derossi D, Prochiantz A, Greene LA, Shelanski ML. Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J Neurosci. 1996;16:253-261.
47. Pooga M, Soomets U, Hällbrink M, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol. 1998;16:857-861.
48. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 1997;25:2730-2736.
49. Mazel M, Clair P, Rousselle C, et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs. 2001;12:107-116.
50. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
51. Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit. 1998;20:588-590.
52. Bolton SJ, Jones DN, Darker JG, Eggleston DS, Hunter AJ, Walsh FS. Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain. Eur J Neurosci. 2000;12:2847-2855.
53. Rousselle C, Clair P, Temsamani J, Schermann JM. Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target. 2002;10:309-315.
54. Schwarze SR, HO a, VoceroAkbani A, Dowdy SF. In vivo protein transduction of a biologically active protein in the mouse. Science. 1999;285:1569-1572.
55. Hardebo JE, Kahrstrom J. Endothelial negative surface charge areas, and blood-brain barrier function. Acta Physiol Scand. 1985;125:495-499.
56. Vordbrodt AW. Ultrastructural cytochemistry of blood-brain barrier endothelial. Prog Histochem Cytochem. 1988;18:1-99.
57. Barr RS, DeRose A, Sandra A, Peacock ML, Owen WG. Insulin binding to microvascular endothelium of intact heart a kinetic and morphometric analysis. Am J Physiol. 1983;244:477-482.
58. Virgintino D. Monaghan P, Robertson D, et al. an immunohistochemical and morphometric study on astrocytes and microvasculature in the human cerebral cortex. Histochem J. 1997;29:655-660.
59. Bertossi M, Virgintino D, Maiorano E, Occhiogrosso M, Roncali L. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol. 1997;21:41-49.